UNC1062，一种新型强效 Mer 抑制剂。
UNC1062, a new and potent Mer inhibitor.
机构信息
Center for Integrative Chemical Biology and Drug Discovery, Division of Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
出版信息
Eur J Med Chem. 2013 Jul;65:83-93. doi: 10.1016/j.ejmech.2013.03.035. Epub 2013 Apr 2.
Abstract
Abnormal activation of Mer kinase has been implicated in the oncogenesis of many human cancers including acute lymphoblastic and myeloid leukemia, non-small cell lung cancer, and glioblastoma. We have discovered a new family of small molecule Mer inhibitors, pyrazolopyrimidine sulfonamides, that potently inhibit the kinase activity of Mer. Importantly, these compounds do not demonstrate significant hERG activity in the PatchXpress assay. Through structure-activity relationship studies, 35 (UNC1062) was identified as a potent (IC50 = 1.1 nM) and selective Mer inhibitor. When applied to live tumor cells, UNC1062 inhibited Mer phosphorylation and colony formation in soft agar. Given the potential of Mer as a therapeutic target, UNC1062 is a promising candidate for further drug development.
摘要
Mer 激酶的异常激活与多种人类癌症的发生有关，包括急性淋巴细胞白血病和髓系白血病、非小细胞肺癌和神经胶质瘤。我们发现了一类新的小分子 Mer 抑制剂——吡唑并嘧啶磺酰胺，它们能强烈抑制 Mer 的激酶活性。重要的是，这些化合物在 PatchXpress 测定中没有表现出明显的 hERG 活性。通过构效关系研究，确定 35（UNC1062）为一种有效的（IC50 = 1.1 nM）和选择性 Mer 抑制剂。当应用于活肿瘤细胞时，UNC1062 抑制 Mer 磷酸化和软琼脂中的集落形成。鉴于 Mer 作为治疗靶点的潜力，UNC1062 是进一步药物开发的有前途的候选药物。
相似文献
1
UNC1062, a new and potent Mer inhibitor.UNC1062，一种新型强效 Mer 抑制剂。
Eur J Med Chem. 2013 Jul;65:83-93. doi: 10.1016/j.ejmech.2013.03.035. Epub 2013 Apr 2.
2
Efficacy of a Mer and Flt3 tyrosine kinase small molecule inhibitor, UNC1666, in acute myeloid leukemia.Mer和Flt3酪氨酸激酶小分子抑制剂UNC1666在急性髓系白血病中的疗效
Oncotarget. 2015 Mar 30;6(9):6722-36. doi: 10.18632/oncotarget.3156.
3
Discovery of 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine derivatives as novel selective Axl inhibitors.发现 5,6,7,8-四氢吡啶并[3,4-d]嘧啶衍生物为新型选择性 Axl 抑制剂。
Bioorg Med Chem Lett. 2021 Sep 15;48:128247. doi: 10.1016/j.bmcl.2021.128247. Epub 2021 Jul 13.
4
UNC2025, a potent and orally bioavailable MER/FLT3 dual inhibitor.UNC2025，一种强效且口服生物可利用的MER/FLT3双重抑制剂。
J Med Chem. 2014 Aug 28;57(16):7031-41. doi: 10.1021/jm500749d. Epub 2014 Aug 6.
5
Pseudo-cyclization through intramolecular hydrogen bond enables discovery of pyridine substituted pyrimidines as new Mer kinase inhibitors.通过分子内氢键实现伪环化，发现吡啶取代嘧啶类化合物作为新型 Mer 激酶抑制剂。
J Med Chem. 2013 Dec 12;56(23):9683-92. doi: 10.1021/jm401387j. Epub 2013 Nov 20.
6
Design, synthesis, biological evaluation and cellular imaging of imidazo[4,5-b]pyridine derivatives as potent and selective TAM inhibitors.设计、合成、生物评价和细胞成像的咪唑并[4,5-b]吡啶衍生物作为有效的和选择性的 TAM 抑制剂。
Bioorg Med Chem. 2018 Nov 1;26(20):5510-5530. doi: 10.1016/j.bmc.2018.09.031. Epub 2018 Sep 25.
7
Discovery of Mer specific tyrosine kinase inhibitors for the treatment and prevention of thrombosis.用于治疗和预防血栓形成的 Mer 特异性酪氨酸激酶抑制剂的发现。
J Med Chem. 2013 Dec 12;56(23):9693-700. doi: 10.1021/jm4013888. Epub 2013 Nov 20.
8
Effects of MERTK Inhibitors UNC569 and UNC1062 on the Growth of Acute Myeloid Leukaemia Cells.MERTK抑制剂UNC569和UNC1062对急性髓系白血病细胞生长的影响
Anticancer Res. 2018 Jan;38(1):199-204. doi: 10.21873/anticanres.12208.
9
UNC569, a novel small-molecule mer inhibitor with efficacy against acute lymphoblastic leukemia in vitro and in vivo.UNC569，一种新型小分子 MER 抑制剂，在体外和体内均对急性淋巴细胞白血病有效。
Mol Cancer Ther. 2013 Nov;12(11):2367-77. doi: 10.1158/1535-7163.MCT-13-0040. Epub 2013 Aug 30.
10
Discovery of N-[4-(Quinolin-4-yloxy)phenyl]benzenesulfonamides as Novel AXL Kinase Inhibitors.发现 N-[4-(喹啉-4-基氧基)苯基]苯磺酰胺类新型 AXL 激酶抑制剂。
J Med Chem. 2018 Jul 26;61(14):6277-6292. doi: 10.1021/acs.jmedchem.8b00672. Epub 2018 Jul 9.
引用本文的文献
1
Discovery of Novel 2-Substituted Aniline Pyrimidine Based Derivatives as Potent Mer/c-Met Dual Inhibitors with Improvement Bioavailability.新型2-取代苯胺嘧啶类衍生物作为具有改善生物利用度的强效Mer/c-Met双重抑制剂的发现。
Biomolecules. 2025 Aug 18;15(8):1180. doi: 10.3390/biom15081180.
2
Exploiting structural variability in the kinase back-pocket to modulate polypharmacology of TAM inhibitors.利用激酶后口袋中的结构变异性来调节TAM抑制剂的多药理学特性。
Eur J Med Chem. 2025 Jun 5;290:117561. doi: 10.1016/j.ejmech.2025.117561. Epub 2025 Mar 28.
3
UNC9426, a Potent and Orally Bioavailable TYRO3-Specific Inhibitor.UNC9426，一种强效且口服生物可利用的TYRO3特异性抑制剂。
J Med Chem. 2025 Mar 27;68(6):6665-6682. doi: 10.1021/acs.jmedchem.5c00048. Epub 2025 Mar 11.
4
Novel Compound MMV1804559 from the Global Health Priority Box Exhibits In Vitro and In Vivo Activity against .新型化合物 MMV1804559 来自全球健康重点药物清单，表现出体外和体内抗. 的活性。
Int J Mol Sci. 2024 Jun 5;25(11):6227. doi: 10.3390/ijms25116227.
5
Discovery of pyrazolopyrimidines that selectively inhibit CSF-1R kinase by iterative design, synthesis and screening against glioblastoma cells.通过针对胶质母细胞瘤细胞的迭代设计、合成和筛选发现选择性抑制CSF-1R激酶的吡唑并嘧啶类化合物。
RSC Med Chem. 2023 Oct 11;14(12):2611-2624. doi: 10.1039/d3md00454f. eCollection 2023 Dec 13.
6
Two-Front War on Cancer-Targeting TAM Receptors in Solid Tumour Therapy.实体瘤治疗中针对肿瘤相关巨噬细胞受体的癌症双线作战
Cancers (Basel). 2022 May 18;14(10):2488. doi: 10.3390/cancers14102488.
7
MERTK Inhibition: Potential as a Treatment Strategy in EGFR Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer.MERTK抑制：作为表皮生长因子受体酪氨酸激酶抑制剂耐药性非小细胞肺癌治疗策略的潜力。
Pharmaceuticals (Basel). 2021 Feb 6;14(2):130. doi: 10.3390/ph14020130.
8
Recent developments in anticancer kinase inhibitors based on the pyrazolo[3,4-]pyrimidine scaffold.基于吡唑并[3,4 - ]嘧啶骨架的抗癌激酶抑制剂的最新进展。
RSC Med Chem. 2020 Sep 8;11(10):1112-1135. doi: 10.1039/d0md00227e. eCollection 2020 Oct 1.
9
Development of the phenylpyrazolo[3,4-]pyrimidine-based, insulin-like growth factor receptor/Src/AXL-targeting small molecule kinase inhibitor.苯并吡唑并[3,4-d]嘧啶基胰岛素样生长因子受体/Src/Axl 靶向小分子激酶抑制剂的开发。
Theranostics. 2021 Jan 1;11(4):1918-1936. doi: 10.7150/thno.48865. eCollection 2021.
10
Crystal Structure of the Kinase Domain of MerTK in Complex with AZD7762 Provides Clues for Structure-Based Drug Development.MerTK 激酶结构域与 AZD7762 复合物的晶体结构为基于结构的药物开发提供了线索。
Int J Mol Sci. 2020 Oct 23;21(21):7878. doi: 10.3390/ijms21217878.
本文引用的文献
1
MERTK receptor tyrosine kinase is a therapeutic target in melanoma.MERTK 受体酪氨酸激酶是黑色素瘤的治疗靶点。
J Clin Invest. 2013 May;123(5):2257-67. doi: 10.1172/JCI67816. Epub 2013 Apr 15.
2
Aberrant Mer receptor tyrosine kinase expression contributes to leukemogenesis in acute myeloid leukemia.异常的 Mer 受体酪氨酸激酶表达导致急性髓系白血病的白血病发生。
Oncogene. 2013 Nov 14;32(46):5359-68. doi: 10.1038/onc.2013.40. Epub 2013 Mar 11.
3
Inhibition of MerTK increases chemosensitivity and decreases oncogenic potential in T-cell acute lymphoblastic leukemia.抑制 MerTK 可提高 T 细胞急性淋巴细胞白血病的化疗敏感性并降低其致癌潜能。
Blood Cancer J. 2013 Jan 25;3(1):e101. doi: 10.1038/bcj.2012.46.
4
Mer or Axl receptor tyrosine kinase inhibition promotes apoptosis, blocks growth and enhances chemosensitivity of human non-small cell lung cancer.-Mer 或 Axl 受体酪氨酸激酶抑制促进人非小细胞肺癌细胞凋亡，阻断生长并增强化疗敏感性。
Oncogene. 2013 Jul 18;32(29):3420-31. doi: 10.1038/onc.2012.355. Epub 2012 Aug 13.
5
Discovery of Novel Small Molecule Mer Kinase Inhibitors for the Treatment of Pediatric Acute Lymphoblastic Leukemia.发现用于治疗小儿急性淋巴细胞白血病的新型小分子Mer激酶抑制剂
ACS Med Chem Lett. 2012 Feb 9;3(2):129-134. doi: 10.1021/ml200239k.
6
Mer receptor tyrosine kinase promotes invasion and survival in glioblastoma multiforme.Mer 受体酪氨酸激酶促进多形性胶质母细胞瘤的侵袭和存活。
Oncogene. 2013 Feb 14;32(7):872-82. doi: 10.1038/onc.2012.104. Epub 2012 Apr 2.
7
Mer receptor tyrosine kinase inhibition impedes glioblastoma multiforme migration and alters cellular morphology.促卵泡激素受体酪氨酸激酶抑制阻碍胶质母细胞瘤的迁移并改变细胞形态。
Oncogene. 2012 Sep 20;31(38):4171-81. doi: 10.1038/onc.2011.588. Epub 2011 Dec 19.
8
TAM receptors in leukemia: expression, signaling, and therapeutic implications.白血病中的TAM受体：表达、信号传导及治疗意义
Crit Rev Oncog. 2011;16(1-2):47-63. doi: 10.1615/critrevoncog.v16.i1-2.60.
9
Microwave-assisted, divergent solution-phase synthesis of 1,3,6-trisubstituted pyrazolo[3,4-d]pyrimidines.微波辅助、发散性溶液相合成 1,3,6-三取代吡唑并[3,4-d]嘧啶。
ACS Comb Sci. 2011 Jul 11;13(4):414-20. doi: 10.1021/co200039k. Epub 2011 May 10.
10
Phosphoproteomic screen identifies potential therapeutic targets in melanoma.磷酸化蛋白质组学筛选鉴定黑色素瘤中的潜在治疗靶点。
Mol Cancer Res. 2011 Jun;9(6):801-12. doi: 10.1158/1541-7786.MCR-10-0512. Epub 2011 Apr 26.
Zotero 插件